"Our wretched species is so made that those who walk on the well-trodden path always throw stones at those who are showing a new road." ? Voltaire
Today we look at a small oncology concern in my portfolio that has doubled recently thanks to encouraging results from a key trial. Is there more upside ahead for this "Tier 4" biotech outfit? Let's take a look.
Company Overview:
TG Therapeutics (NASDAQ: TGTX) is a biopharmaceutical company focused on developing novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes and TGR-1202 is an orally available PI3K delta inhibitor for various hematologic malignancies. The company is currently valued at approximately $600 million and trades for just over $10.00 a share.
